Magnus Financial Group LLC raised its stake in shares of BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) by 105.0% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 71,733 shares of the company's stock after buying an additional 36,733 shares during the period. Magnus Financial Group LLC owned about 0.44% of BioHarvest Sciences worth $444,000 at the end of the most recent quarter.
Separately, TD Waterhouse Canada Inc. purchased a new position in shares of BioHarvest Sciences during the 4th quarter valued at about $69,000.
BioHarvest Sciences Trading Up 1.2%
Shares of BioHarvest Sciences stock opened at $6.96 on Friday. BioHarvest Sciences Inc. has a twelve month low of $4.66 and a twelve month high of $7.38. The company has a 50-day simple moving average of $6.18. The stock has a market cap of $114.32 million, a price-to-earnings ratio of -5.57 and a beta of 0.58.
BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.02. The business had revenue of $7.64 million during the quarter, compared to analysts' expectations of $8.93 million. Sell-side analysts anticipate that BioHarvest Sciences Inc. will post -0.8 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of equities analysts have weighed in on BHST shares. Craig Hallum started coverage on BioHarvest Sciences in a research note on Monday, May 5th. They set a "buy" rating and a $15.00 price objective for the company. HC Wainwright restated a "buy" rating and issued a $14.00 price target on shares of BioHarvest Sciences in a research note on Tuesday, April 8th.
Check Out Our Latest Report on BHST
BioHarvest Sciences Company Profile
(
Free Report)
BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.
Further Reading
Want to see what other hedge funds are holding BHST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioHarvest Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioHarvest Sciences wasn't on the list.
While BioHarvest Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
